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Background
Skeletal muscle is a key peripheral metabolic tissue: Mus-
cle is responsible for most insulin-stimulated glucose
uptake, and muscle insulin resistance is the first defect
detectable in the development of type 2 diabetes. Recent
studies show that muscle mass is inversely correlated with
insulin resistance in humans. The growth factor myostatin
(MSTN) is a negative regulator of skeletal muscle size.
Mstn KO mice or mice expressing a dominant negative
activin type receptor type IIB (Acrv2B) specifically in mus-
cle (Muscle-DN mice) have increased muscle mass,
reduced adipose mass and improved insulin sensitivity.
The improvements in insulin sensitivity could be due to
the direct effects of the loss of MSTN in muscle or to the
secondary effects of reduced adiposity or both. Our
hypothesis is that MSTN inhibition specifically in the
muscle can improve hyperglycemia in diabetic mice inde-
pendent of changes in adiposity. To test this hypothesis,
we inhibited MSTN signaling in a diabetic model of gener-
alized lipodystrophy (A-ZIP/F-1 mouse model) to analyze
its effects on glucose metabolism separate from effects on
adipose mass. The A-ZIP/F-1 fatless mouse is a model of
lipodystrophy characterized by the lack of white adipose
tissue, diabetes, ectopic lipid accumulation and
hyperphagia.
Materials and methods
MSTN signaling was inhibited in A-ZIP/F-1 mice by
crossing them to Muscle-DN mice or by injection of
soluble Acrv2B. Blood glucose, insulin, insulin sensitivity,
triglyceride levels, and food intake were analyzed. The
effects of blood glucose on food intake were examined in
AZIP/F-1 mice by administration of Phloridzin.
Results
The development of hyperglycemia, hyperinsulinemia
and lipidemia in A-ZIP/F-1 mice was completely sup-
pressed by blocking MSTN function in muscle. Blocking
MSTN in A-ZIP/F-1 mice also prevented hyperphagia
without any apparent increase in the adipokine leptin.
Blood glucose and food intake were also reduced by
pharmacologic MSTN inhibition in diabetic A-ZIP/F-1
mice using a soluble receptor. Decreasing blood glucose
in A-ZIP/F-1 mice by administration of Phloridzin did
not alter food intake.
Conclusions
These results show that MSTN inhibition can ameliorate
diabetes in mice and that this response does not depend
on reducing adipose mass. Furthermore, because energy
intake is regulated by the central nervous system, our
results suggest that muscle may send an as yet unknown
signal to the brain, whether directly or indirectly, to regu-
late energy intake.
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